Novartis' decision to withdraw chronic migraine biologic AIMOVIG (erenumab) from last week's PBAC meeting will contribute to achieving the goal of a "50 percent reduction in the number of resubmissions to the PBAC". Was this the intent of the PBS process improvements initiative? …
Reducing submission 'churn' by getting rid of resubmissions?
November 11, 2019 Latest NewsNews of the Day
Latest Video
New Stories
-
The Week in Review Podcast - 19 April
April 19, 2024 - - Podcast -
New Novartis-backed report identifies nuclear medicine opportunity but calls for change
April 19, 2024 - - Latest News -
Scope of practice review recommends formation of new committee
April 19, 2024 - - Latest News -
The HTA review reference committee members should ask themselves one question
April 18, 2024 - - Latest News -
If coercion and retribution are bad for supermarket customers, they must be bad for patients
April 18, 2024 - - Latest News -
AbbVie announces the appointment of new Australia-NZ human resources director
April 18, 2024 - - BioPharma -
'Under Karen’s leadership our local business has thrived both commercially and culturally'
April 18, 2024 - - Latest News